Chek | Jotup

NovaBay Pharmaceuticals Launches Avenova Product Bundles for Individualized Relief from Multifactorial Dry Eye Symptoms

Retrieved on:

星期一, 五月 13, 2024

Biotechnology, Health, Pharmaceutical, Optical, Medical Supplies, Chek, Patient, Telecanthus, Eye, Hygiene, Prevalence, Specialization, NBY, Hypochlorous acid, Demodex, Cosmetics

The new Avenova product bundles align with findings among optometrists surveyed in the Eyes on Eyecare 2024 Dry Eye Report of the multifactorial nature of dry eye disease and the recommendation that personalized treatment beyond artificial tears may be important for successful management.

Key Points:

The new Avenova product bundles align with findings among optometrists surveyed in the Eyes on Eyecare 2024 Dry Eye Report of the multifactorial nature of dry eye disease and the recommendation that personalized treatment beyond artificial tears may be important for successful management.
“Our new Avenova product bundles align with where we see the market going, as confirmed by the 2024 Dry Eye Report.
In addition to Avenova spray, the Avenova over-the-counter product line includes the Avenova Eye Health Support antioxidant-rich oral supplement, Avenova Lubricating Eye Drops for instant relief, Avenova Warm Eye Compress to soothe the eyes and the i-Chek by Avenova to monitor physical eyelid health.
The 2024 Dry Eye Report surveyed 337 optometrists across the U.S., with the majority as primary eye care and dry eye specialists.

NovaBay Pharmaceuticals Announces Record Ordered Product Sales of Avenova-Branded Products in April through Amazon

Retrieved on:

星期二, 五月 7, 2024

Biotechnology, Online Retail, Health, Cosmetics, Retail, Chek, Amazon (company), Marketing, Telecanthus, Growth, NBY

(NYSE American: NBY), a company developing and commercializing high-quality eyecare and wound care products, announces record ordered product sales during the month of April for its Avenova-branded eyecare products on Amazon.com, the Company’s largest sales channel.

Key Points:

(NYSE American: NBY), a company developing and commercializing high-quality eyecare and wound care products, announces record ordered product sales during the month of April for its Avenova-branded eyecare products on Amazon.com, the Company’s largest sales channel.
“We are very excited about our progress with ordered product sales for Avenova on Amazon, including setting a record for ordered product sales in March and then immediately beating that record in April.
Ordered product sales in the previous two months have even eclipsed prior months that included record sales days during Prime Day events,” said Justin Hall, CEO of NovaBay.
We attribute these unparalleled sales months to the high quality of our Avenova products and the effectiveness of those cost-efficient marketing programs.

NovaBay Pharmaceuticals Reports 64% Year-Over-Year Growth in Avenova Unit Subscription-Based Sales

Retrieved on:

星期二, 一月 30, 2024

Biotechnology, Women, Consumer, Health, Optical, Chek, NovaBay Pharmaceuticals, NBY, Amazon (company)

NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces a 64% increase in online subscription-based unit sales for its Avenova® Lid & Lash Spray Solution and a 38% increase in subscription-based customers in 2023 over the prior year on Amazon.com and Avenova.com.

Key Points:

NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces a 64% increase in online subscription-based unit sales for its Avenova® Lid & Lash Spray Solution and a 38% increase in subscription-based customers in 2023 over the prior year on Amazon.com and Avenova.com.
A substantial 24% of all online sales were from subscribers in 2023, up from approximately 14% in 2022.
In addition, of the more than 13,000 customer reviews across all online channels, Avenova Spray averaged a 4.5-star overall rating.
“Generating sales through the subscriber base provides efficient and consistent revenue, allowing us to better manage our sales and marketing spend.

RXBAR® releases resistance bands loaded with rewards to help Canadians crush their fitness goals

Retrieved on:

星期一, 一月 29, 2024

Chek, Abacus Data, Sport Chek, Apple Watch, Marketing, Health, Nightclub

motto and invites Canadians to put the "work" into "workout" by launching limited run resistance bands to help fuel their goals – and even reward them for it.

Key Points:

motto and invites Canadians to put the "work" into "workout" by launching limited run resistance bands to help fuel their goals – and even reward them for it.
Today, RXBAR® protein bar is launching a two-part national giveaway to help Canadians conquer their fitness goals, centered around a limited run of resistance bands aptly named RXBands™.
To give away RXBands™ to fitness enthusiasts across the country, RXBAR® is partnering with three fitness personalities on Instagram.
After all, you get out what you put in, and no workout proves that better than resistance bands."

NovaBay Pharmaceuticals Partners with Woo University to Educate Eyecare Professionals on the Use of Amniotic Membranes

Retrieved on:

星期三, 十二月 6, 2023

Health, Other Health, General Health, Clinical Trials, Pharmaceutical, Optical, Biotechnology, Chek, NBY, NovaBay Pharmaceuticals, NYSE, General counsel, Conjunctiva, Report, Partnership, Education

NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces its partnership with Woo University to support the education of eyecare professionals on the use of amniotic membranes.

Key Points:

NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces its partnership with Woo University to support the education of eyecare professionals on the use of amniotic membranes.
A free webinar is being held Thursday, December 7, 2023 from 5:30-6:30 pm Pacific time, and eyecare professionals can register here .
In September 2023 NovaBay commercially launched its prescription amniotic membrane product Avenova® Allograft, which is intended for use as a protective covering during the repair of ocular surfaces.
Woo University is a non-profit organization committed to providing high-quality continuing education to eyecare professionals around the world.

NovaBay Pharmaceuticals Expands Physician Dispensed Sales Channel with New Avenova Programs

Retrieved on:

星期三, 十月 11, 2023

Through the new Avenova Loyalty Program and Avenova Affiliate Program, top Avenova eyecare professionals will have access to special promotions specifically designed to increase the awareness of the full suite of Avenova products.

Key Points:

Through the new Avenova Loyalty Program and Avenova Affiliate Program, top Avenova eyecare professionals will have access to special promotions specifically designed to increase the awareness of the full suite of Avenova products.
“We have thousands of eye care professionals who recommend, prescribe, and sell our Avenova spray on a daily basis.
1 doctor-recommended lid and lash cleanser and we are delighted to offer these partnership opportunities to grow this important sales channel,” said Justin Hall, CEO of NovaBay Pharmaceuticals.
Ophthalmologists and optometrists interested in learning more about the new Avenova Loyalty and Affiliate Programs should email [email protected] or call 510-899-8841.

NovaBay Pharmaceuticals Announces Commercial Launch of Avenova® Allograft

Retrieved on:

星期四, 九月 14, 2023

Medical Devices, Health, Health Technology, Pharmaceutical, Optical, Biotechnology, Chek, Cornea, General counsel, Conjunctiva, NBY, Ophthalmology, NovaBay Pharmaceuticals, Optometry, Medicare, OTC, NYSE, Pharmaceutical industry

NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces the commercial launch of Avenova Allograft to eyecare professionals across the U.S. through its physician-dispensed channel.

Key Points:

NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces the commercial launch of Avenova Allograft to eyecare professionals across the U.S. through its physician-dispensed channel.
The product launch follows a previously announced agreement under which NovaBay was granted the right to commercialize BioStem Technologies’ Amniotic Tissue Allograft under the Avenova brand.
The Avenova Allograft will compete in the global ophthalmology amniotic membrane market estimated at $403.6 million in 2022, which is expected to grow at 9.8% per year between 2023-2030 .
NovaBay’s commercial launch of Avenova Allograft includes outreach programs aimed at educating eyecare specialists on both the clinical benefits of the product, as well as the process for Medicare reimbursement.

CRITEO REPORTS STRONG SECOND QUARTER 2023 RESULTS

Retrieved on:

星期三, 八月 2, 2023

NEW YORK, Aug. 2, 2023 /PRNewswire/ -- Criteo S.A. (NASDAQ: CRTO) ("Criteo" or the "Company"), the commerce media company, today announced financial results for the three and six months ended June 30, 2023.

Key Points:

"We delivered a strong performance in the second quarter, demonstrating our relentless focus on execution.
We have momentum heading into the second half of the year, and we remain confident in our 2023 growth outlook."
In the course of the second quarter 2023, we incurred $22 million in restructuring, integration and transformation costs.
The above guidance assumes that no additional acquisitions are completed during the third quarter of 2023 or the fiscal year ended December 31, 2023.

NovaBay Pharmaceuticals Reports Record Avenova Sales Day

Retrieved on:

星期五, 七月 14, 2023

(NYSE American: NBY), a company developing and commercializing high-quality eyecare, skincare and wound care products, announces that sales of Avenova®-branded products reached a new record during the Amazon Prime Day event held July 11-12, 2023, with sales increasing 22% over Prime Day 2022 and 43% over Prime Day 2021.

Key Points:

(NYSE American: NBY), a company developing and commercializing high-quality eyecare, skincare and wound care products, announces that sales of Avenova®-branded products reached a new record during the Amazon Prime Day event held July 11-12, 2023, with sales increasing 22% over Prime Day 2022 and 43% over Prime Day 2021.
“Sales of Avenova products during Prime Day 2023 were at an all-time high since we created our direct-to-consumer sales channel in 2019.
Unit sales and revenue broke daily records, eclipsing all previous milestones,” said Justin Hall, NovaBay CEO.
“We are encouraged by this growth in our most important sales channel, and appreciate the loyalty of current Avenova users.

NovaBay Pharmaceuticals Supports National Dry Eye Awareness Month with Educational Programs and Avenova Product Promotions

Retrieved on:

星期三, 六月 28, 2023

(NYSE American: NBY), a company developing and commercializing high-quality eyecare, skincare and wound care products, announces that it will be sponsoring dry eye educational programs and offering special promotions on its Avenova®-branded eyecare products to customers and eyecare professionals throughout July in support of National Dry Eye Awareness Month.

Key Points:

(NYSE American: NBY), a company developing and commercializing high-quality eyecare, skincare and wound care products, announces that it will be sponsoring dry eye educational programs and offering special promotions on its Avenova®-branded eyecare products to customers and eyecare professionals throughout July in support of National Dry Eye Awareness Month.
“Over the years we have consistently heard from patients and eyecare professionals alike that managing chronic dry eye can be a challenge.
Recognizing that a single approach may not be sufficient to gain and sustain relief from the symptoms of dry eye, NovaBay now offers a full line of best-in-class products under the Avenova brand.
NovaBay offers best-in-class Avenova-branded products for each step of the standard dry-eye treatment regimen, including Avenova spray, the No.